Secreted protein acidic and rich in cysteine antagonizes bufalin‑induced apoptosis in gastric cancer cells

Li,Aodi; Qu,Xiujuan; Li,Zhi; Qu,Jinglei; Song,Na; Ma,Yanju; Liu,Yunpeng

doi:10.3892/mmr.2015.3676

Secreted protein acidic and rich in cysteine antagonizes bufalin‑induced apoptosis in gastric cancer cells

Authors:
- Aodi Li
- Xiujuan Qu
- Zhi Li
- Jinglei Qu
- Na Song
- Yanju Ma
- Yunpeng Liu
View Affiliations

Affiliations: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: April 24, 2015 https://doi.org/10.3892/mmr.2015.3676
Pages: 2926-2932

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bufalin is an active compound in the traditional Chinese medicine Chan Su, which has been shown to induce apoptosis in a range of cancer cell types. However, certain gastric cancer cells are known to be resistant to bufalin. Intracellular secreted protein acidic and rich in cysteine (SPARC) regulates proliferation and apoptosis. This study aimed to evaluate the role of SPARC in bufalin‑induced apoptosis in SGC7901 and MGC803 gastric cancer cells. SGC7901 cells with high SPARC expression were more resistant to bufalin than MGC803 cells with low SPARC expression. This resistance was significantly reversed by small interfering (si)RNA‑mediated knockdown of SPARC. Furthermore, it was shown that SPARC negatively regulated bufalin‑induced intrinsic apoptosis by protecting mitochondrial integrity, decreasing the release of cytoplasmic cytochrome c and increasing the ratio of Bcl‑2/Bax. In addition, SPARC overcame bufalin‑induced G2/M phase arrest by increasing levels of Cyclin B1 and Cyclin A protein expression. SPARC also activated cellular survival signals, including Src and Akt, but not extracellular signal‑regulated kinase. This study demonstrated that SPARC antagonizes bufalin‑induced apoptosis via inhibition of the intrinsic apoptosis pathway, inhibition of cell cycle arrest and activation of certain pathways involved in proliferation. This provides novel evidence for SPARC as a potential target by which to sensitize gastric cancer cells to bufalin.

View Figures

View References

1	Kanat O and O’Neil BH: Metastatic gastric cancer treatment: a little slow but worthy progress. Med Oncol. 30:4642013. View Article : Google Scholar : PubMed/NCBI
2	Hong Z, Chan K and Yeung HW: Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, liu-shen-wan, by liquid chromatography. J Pharm Pharmacol. 44:1023–1026. 1992. View Article : Google Scholar : PubMed/NCBI
3	Panesar NS: Bufalin radioimmunoassays: in search of the endogenous digitalis-like substance. J Immunoassay. 15:371–391. 1994. View Article : Google Scholar : PubMed/NCBI
4	Kang XH, Xu ZY, Gong YB, et al: Bufalin reverses HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via blockage of Met/PI3k/Akt pathway and induction of apoptosis. Evid Based Complement Alternat Med. 2013:2438592013. View Article : Google Scholar : PubMed/NCBI
5	Yan S, Qu X, Xu C, et al: Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 138:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhang DM, Liu JS, Tang MK, et al: Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Eur J Pharmacol. 692:19–28. 2012. View Article : Google Scholar : PubMed/NCBI
7	Watabe M, Ito K, Masuda Y, Nakajo S and Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene. 16:779–787. 1998. View Article : Google Scholar : PubMed/NCBI
8	Qi F, Inagaki Y, Gao B, et al: Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hsiao YP, Yu CS, Yu CC, et al: Triggering apoptotic death of human malignant melanoma a375.s2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways. Evid Based Complement Alternat Med. 2012:5912412012. View Article : Google Scholar : PubMed/NCBI
10	Huang WW, Yang JS, Pai SJ, et al: Bufalin induces G(0)/G(1) phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutat Res. 732:26–33. 2012. View Article : Google Scholar : PubMed/NCBI
11	Li D, Qu X, Hou K, et al: PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 20:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yan Q and Sage EH: SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem. 47:1495–1506. 1999. View Article : Google Scholar : PubMed/NCBI
13	Seux M, Peuget S, Montero MP, et al: TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression. Oncogene. 30:3049–3061. 2011. View Article : Google Scholar : PubMed/NCBI
14	Azim HA Jr, Singhal S, Ignatiadis M, et al: Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One. 8:e624512013. View Article : Google Scholar : PubMed/NCBI
15	Shin M, Mizokami A, Kim J, et al: Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. Prostate. 73:1159–1170. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yin J, Chen G, Liu Y, et al: Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. J Exp Clin Cancer Res. 29:592010. View Article : Google Scholar : PubMed/NCBI
17	Desai N, Trieu V, Damascelli B and Soon-Shiong P: SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
18	Von Hoff DD, Ramanathan RK, Borad MJ, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
19	Demeure MJ, Stephan E, Sinari S, et al: Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg. 255:140–146. 2012. View Article : Google Scholar
20	Guarneri V, Dieci MV and Conte P: Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother. 13:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chen J, Shi D, Liu X, Fang S, Zhang J and Zhao Y: Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis. BMC Cancer. 12:4642012. View Article : Google Scholar : PubMed/NCBI
22	Chen J, Wang M, Xi B, et al: SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One. 7:e424132012. View Article : Google Scholar : PubMed/NCBI
23	Fenouille N, Puissant A, Tichet M, et al: SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene. 30:4887–4900. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gorantla B, Bhoopathi P, Chetty C, et al: Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma. Angiogenesis. 16:85–100. 2013. View Article : Google Scholar
25	Seno T, Harada H, Kohno S, Teraoka M, Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol. 34:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
26	Horie K, Tsuchihara M and Nakatsura T: Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci. 101:913–919. 2010. View Article : Google Scholar : PubMed/NCBI
27	Sengupta S and Chattopadhyay MK: Lowry’s method of protein estimation: Some more insights. J Pharm Pharmacol. 45:801993. View Article : Google Scholar
28	Giallongo C, La Cava P, Tibullo D, et al: SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. BMC Cancer. 13:602013. View Article : Google Scholar : PubMed/NCBI
29	Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C and Rempel SA: Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer. 11:202012. View Article : Google Scholar : PubMed/NCBI
30	Rahman M, Chan AP and Tai IT: A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One. 6:e263902011. View Article : Google Scholar : PubMed/NCBI
31	Fenouille N, Robert G, Tichet M, et al: The p53/p21Cip1/Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res. 24:219–232. 2011. View Article : Google Scholar
32	Jiang Y, Zhang Y, Luan J, et al: Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology. 62:573–583. 2010. View Article : Google Scholar : PubMed/NCBI
33	Zhu Z, Sun H, Ma G, et al: Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway. Int J Mol Sci. 13:2025–2035. 2012. View Article : Google Scholar : PubMed/NCBI
34	Li H, Wang P, Gao Y, et al: Na⁺/K⁺-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol Rep. 25:825–830. 2011.
35	Li Y, Chen L, Chan TH, et al: SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology. 144:179–191. 2013. View Article : Google Scholar
36	Said N, Najwer I and Motamed K: Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol. 170:1054–1063. 2007. View Article : Google Scholar : PubMed/NCBI
37	Liu H, Xu Y, Chen Y, et al: RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells. Oncol Lett. 2:985–990. 2011.
38	Bhoopathi P, Gondi CS, Gujrati M, Dinh DH and Lakka SS: SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42. Cell Signal. 23:1978–1987. 2011. View Article : Google Scholar : PubMed/NCBI